Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey

What Was Tested

The paper reports a study of Octreotide, published as a randomized controlled trial.

To determine the impact of a phase III randomised controlled trial on palliative care clinicians' self-reported practice change.

Why It Was Studied

Translating research evidence into clinical practice often has a long lag time.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Online survey about use of octreotide in managing inoperable malignant bowel obstruction due to cancer or its treatments distributed in November 2016, 2 years after the first publication of the study in a peer-reviewed journal.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Demographic, self-reported practice and the reasons underpinning this were collected.

Responses were aggregated to 'practice modified' or 'practice not modified'.

A multinomial regression model explored predictors of practice change.

What Was Measured

PubMed files the paper under topics including Antineoplastic Agents, Hormonal, Australia, Colorectal Neoplasms, Intestinal Obstruction, Octreotide, Oncologists and Palliative Care.

The authors tagged it with the keywords Practice change, implementation science, malignant bowel obstruction, phase III clinical trial, randomised controlled trial and somatostatin analogues.

What This Means in Plain Language

The paper is a randomized study of Octreotide.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Palliative medicine), a journal based in England.

More context: the Octreotide compound page, all human trials.